Literature DB >> 24463713

[The role of pathology in the diagnostics of CUP syndrome].

A Stenzinger1, M Kriegsmann, W Weichert.   

Abstract

Cancers of unknown primary (CUP) origin account for 2-3 % of all malignancies in Germany and represent a heterogeneous, often aggressive and clinically challenging group of tumors with early metastatic dissemination for which a standardized diagnostic work-up initially fails to identify the primary site of origin at the time of diagnosis. This article reviews the options and challenges of tissue-based conventional as well as molecular diagnostic procedures to categorize this heterogeneous group of neoplasms. The role of pathology in the diagnostics of CUP syndrome is described as part of a multidisciplinary effort involving oncologists, surgeons and radiologists with the ultimate goal of assisting clinical reasoning and decision-making.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24463713     DOI: 10.1007/s00117-013-2546-x

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  31 in total

Review 1.  Clinical applications of immunohistochemistry in gynecological malignancies.

Authors:  J Shutter; K A Atkins; K Ghartey; T J Herzog
Journal:  Int J Gynecol Cancer       Date:  2007 Mar-Apr       Impact factor: 3.437

Review 2.  Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls.

Authors:  Doina Ivan; Victor G Prieto
Journal:  Future Oncol       Date:  2010-07       Impact factor: 3.404

3.  Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.

Authors:  Daniel S-W Tan; Joey Montoya; Quan-Sing Ng; Kian-Sing Chan; Oon Lynette; Sai Sakktee Krisna; Angela Takano; Wan-Teck Lim; Eng-Huat Tan; Kiat-Hon Lim
Journal:  J Clin Oncol       Date:  2013-04-01       Impact factor: 44.544

Review 4.  Role of immunohistochemistry in diagnosing renal neoplasms: when is it really useful?

Authors:  Steven S Shen; Luan D Truong; Marina Scarpelli; Antonio Lopez-Beltran
Journal:  Arch Pathol Lab Med       Date:  2012-04       Impact factor: 5.534

Review 5.  Cancer of unknown primary site.

Authors:  Nicholas Pavlidis; George Pentheroudakis
Journal:  Lancet       Date:  2012-03-12       Impact factor: 79.321

6.  Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.

Authors:  Barbara A Centeno; Gregory Bloom; Dung-Tsa Chen; Zhihua Chen; Mike Gruidl; Aejaz Nasir; Timothy Y Yeatman
Journal:  J Mol Diagn       Date:  2010-06-17       Impact factor: 5.568

7.  Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging.

Authors:  Stephan Meding; Ulrich Nitsche; Benjamin Balluff; Mareike Elsner; Sandra Rauser; Cédrik Schöne; Martin Nipp; Matthias Maak; Marcus Feith; Matthias P Ebert; Helmut Friess; Rupert Langer; Heinz Höfler; Horst Zitzelsberger; Robert Rosenberg; Axel Walch
Journal:  J Proteome Res       Date:  2012-02-03       Impact factor: 4.466

Review 8.  Neuroendocrine carcinoma of unknown primary site.

Authors:  David R Spigel; John D Hainsworth; F Anthony Greco
Journal:  Semin Oncol       Date:  2009-02       Impact factor: 4.929

9.  Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens.

Authors:  Mi Jin Kim; Hyeong Chan Shin; Kyeong Cheol Shin; Jae Y Ro
Journal:  Ann Diagn Pathol       Date:  2012-10-04       Impact factor: 2.090

Review 10.  Molecular classification of cancers of unknown primary site.

Authors:  F Anthony Greco; Mark G Erlander
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.